Crossmark

High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria

Crossref DOI link: https://doi.org/10.1007/s00415-019-09191-6

Published Online: 2019-01-16

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Topakian, Raffi

Zimprich, Fritz

Iglseder, Stephan

Embacher, Norbert

Guger, Michael

Stieglbauer, Karl

Langenscheidt, Dieter

Rath, Jakob

Quasthoff, Stefan

Simschitz, Philipp

Wanschitz, Julia

Windisch, David

Müller, Petra

Oel, Dierk

Schustereder, Günther

Einsiedler, Stefan

Eggers, Christian

Löscher, Wolfgang
License Information

Text and Data Mining valid from 2019-01-16
More Information

Article History

Received: 18 November 2018

Revised: 1 January 2019

Accepted: 6 January 2019

First Online: 16 January 2019

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.